Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206765 · ClinicalTrials.gov registry record · Phase 2
Risperidone vs. Paroxetine for Panic Attacks
A Phase 2 study, sponsored by Beth Israel Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00206765 is a Phase 2 study that was terminated before completion, run by Beth Israel Medical Center. The registered enrollment target is 90 participants.
The verdict
NCT00206765, a Phase 2 study, was terminated before completion, sponsored by Beth Israel Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
We are comparing the efficacy of Risperidone versus Paroxetine in the treatment of panic symptoms. The study hypothesis is that Risperidone will be a superior medicine for treating panic.
Interventions
- DRUG Risperidone
- DRUG Paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206765
The ClinicalTrials.gov registry entry for NCT00206765 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Medical Center, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT00206765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206765 about?
NCT00206765 is a clinical study titled "Risperidone vs. Paroxetine for Panic Attacks". We are comparing the efficacy of Risperidone versus Paroxetine in the treatment of panic symptoms. The study hypothesis is that Risperidone will be a superior medicine for treating panic.
What is the current status of trial NCT00206765?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2003-01. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00206765?
The interventions under investigation include: Risperidone (DRUG), Paroxetine (DRUG).
Who is sponsoring clinical trial NCT00206765?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.